VivoSeq
Other

Erythropoietin

0

Pipeline Programs↗

3

Active Trials↗

9

Companies Involved↗

Erythropoietin is an early-stage landscape with 0 programs across 9 companies. The most active players are Roche, Hanmi Pharmaceutical Company Limited, Shenyang Sunshine Pharmaceutical Co., LTD..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

PreclinicalHanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited

0 programs

PreclinicalS

Shenyang Sunshine Pharmaceutical Co., LTD.

0 programs

PreclinicalS

Shenzhen Salubris Pharmaceuticals Co., Ltd.

0 programs

PreclinicalI

Incepta Pharmaceuticals Ltd

0 programs

PreclinicalS

Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

59

clinical trials

Completed35 · 59%
Unknown status12 · 20%
Terminated7 · 12%
Not yet recruiting2 · 3%
Withdrawn2 · 3%
Recruiting1 · 2%

Clinical Trials

Trial Activity

59 trials

PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).
Recruiting·IIncepta Pharmaceuticals Ltd·Phase 3·NCT07025681·56 enrolled
Erythropoietin in HIE Neonate
Not yet recruiting·—·Phase 1·NCT06590155·3 enrolled
Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers
Not yet recruiting·MMegalabs·Phase 1·NCT04954989·52 enrolled
A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects
Completed·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 1·NCT01013064·48 enrolled
Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis
Completed·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 3·NCT06720025·100 enrolled
The Clinical Evaluation of the Dose of Erythropoietins Trial
Completed·GGiovanni FM Strippoli, MD·Phase 3·NCT00827021·656 enrolled
Optimized Erythropoietin (EPO) Treatment
Completed·—·Phase 2·NCT02075970·62 enrolled
Comparison Among Erythropoietin Stimulating Agents
Completed·HHamad Medical Corporation·Phase 4·NCT02049346·327 enrolled
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
Completed·Roche logoRoche·Phase 3·NCT02767765·61 enrolled
Renal Effects of Erythropoietin in Humans
Completed·UUniversity of Copenhagen·Phase 1·NCT01584921·16 enrolled
Does Erythropoietin Improve Outcome in Very Preterm Infants?
Completed·SSwiss Neonatal Network·Phase 2·NCT00413946·420 enrolled
A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects
Completed·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 1·NCT01030315·65 enrolled
The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)
Completed·UUniversity of Calgary·Phase 2·NCT00336466·32 enrolled
Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome
Completed·UUMC Utrecht·Phase 3·NCT00356733·62 enrolled
The Effect of Human Recombinant Erythropoietin in Acute Renal Failure
Completed·NNorth Texas Veterans Healthcare System·Phase 2·NCT03102021·25 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)